# Sources — Georgia O'Keeffe

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 2, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Georgia O’Keeffe Museum. Chronology (accessible site). Supports her birth on November 15, 1887, to Francis Calyxtus O’Keeffe and Ida Totto O’Keeffe at the family dairy farm near Sun Prairie, Wisconsin; her mother’s death in Charlottesville in May 1916 and her father’s in Petersburg in November 1918; two operations for benign breast cysts at Mount Sinai in 1927; admission to Doctor’s Hospital in February 1933 “suffering from psychoneurosis” and recuperation in Bermuda; failing eyesight beginning in 1968; loss of central vision early in 1971 with only peripheral sight retained; her last unassisted oil painting in 1972 and later work with assistance; Juan Hamilton as her assistant from 1973 and her work in clay from 1974; and her death at St. Vincent’s Hospital, Santa Fe, on March 6, 1986. https://access-ok.okeeffemuseum.org/chronology/
2. Georgia O’Keeffe Museum. Biography (accessible site). Supports her birth on November 15, 1887, as the second of seven children on a farm near Sun Prairie; macular degeneration and failing vision; the last unassisted oil painting in 1972; and her death in Santa Fe at 98. https://access-ok.okeeffemuseum.org/biography/
3. Whitney Museum of American Art. Exhibition text on her late watercolors. Supports macular degeneration beginning in early 1971 that eventually left her with only peripheral vision, work with assistants in her early eighties, and her death in Santa Fe at 98 on March 6, 1986. https://whitney.org/media/632
4. The Vision & Art Project (American Macular Degeneration Foundation). “Georgia O’Keeffe.” Secondary source. Quotes a 1972 letter, as cited in Jeffrey Hogrefe’s 1992 biography, in which she wrote that her left eye had become much more cloudy and her right eye seemed to be beginning to cloud; suggests first signs as early as 1964 (graded **R**, possible). https://visionandartproject.org/artists/georgia-okeeffe/
5. HISTMED Master Roster v3. Internal project source. Its clinical claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. American Academy of Ophthalmology. Age-Related Macular Degeneration Preferred Practice Pattern (2024; *Ophthalmology*, 2025). Prompt evaluation of new distortion, OCT and angiography, intravitreal anti-VEGF therapy with monthly loading and treat-and-extend dosing, pressure checks after injection, AREDS2 supplements for intermediate AMD, home Amsler grid monitoring, and low-vision rehabilitation. https://doi.org/10.1016/j.ophtha.2024.12.018
2. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), cataract and glaucoma monographs. AMD is not one of the 30 CMS conditions, so only the general eye-examination items are used: best-corrected acuity and tonometry at each comprehensive eye examination, functional impairment assessment, and an annual comprehensive eye evaluation at age 65 or older. Depression and cognitive screening at 65 or older follow the general CMID items. https://patrickrutledge.github.io/topthirty/
3. Vuurberg G, et al. “Diagnosis, treatment and prevention of ankle sprains: update of an evidence-based clinical guideline.” *Br J Sports Med* 2018;52(15):956. The Ottawa ankle rules to decide on radiographs, functional support with a brace and early exercise therapy rather than immobilization, and analgesia. Used for the sick visit. https://pubmed.ncbi.nlm.nih.gov/29514819/
4. Centers for Medicare & Medicaid Services. Medicare Wellness Visits (Medicare Learning Network). Required elements of the subsequent annual wellness visit: health risk assessment review, updated history and medication list, measurements, cognitive assessment, depression and functional screening, and the written prevention plan, with optional same-day advance care planning. https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html
5. Medicare Preventive Services reference (Aether Forge, 2026). The annual wellness visit template (history of present illness fields, review of systems, examination, assessment and plan, and the screening cascade) that the visit note follows. https://patrickrutledge.github.io/preventative_services/
6. U.S. Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening (2025), and Falls Prevention in Community-Dwelling Older Adults: Interventions (2024). Bone density screening for women 65 and older; exercise for older adults at increased fall risk. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening and https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/falls-prevention-community-dwelling-older-adults-interventions

## Editorial resolutions

- **Index age.** The modern episode presents O’Keeffe at 80, her age in 1968, when the museum chronology records that her eyesight began to fail. The synthetic date of birth is November 15, 1945 (shift 58 years), so the chronic-care visits from March to July 2026 map to March to July 1968; the sick and wellness visits are described below. Past medical history and family history include only events before the index date; the 1971 loss of central vision, her later work with assistants, and her death remain in the historical timeline.
- **Type of macular degeneration.** The sources say macular degeneration but not whether it was dry or neovascular. The modern episode makes the left eye neovascular and the right eye intermediate dry AMD, consistent with the 1972 letter describing the left eye as worse. Both are synthetic.
- **Teaching contrast.** Her documented course, from failing sight in 1968 to central vision loss in 1971, happened before anti-VEGF therapy existed. The synthetic episode shows what modern treatment and monitoring would offer; it does not claim that treatment would have changed her course.
- **1933 hospitalization.** The museum chronology records “psychoneurosis.” The term is kept as recorded and marked sensitive; no modern psychiatric diagnosis is inferred or coded, so no safety assessment is required.
- **Earlier onset.** The suggestion that first signs appeared as early as 1964 comes from a secondary advocacy source and is graded **R**, possible. It is kept off the problem list.
- **Sick and wellness visits.** Two visits were added after the chronic-care schedule: an unscheduled sick visit on August 20, 2026 (true frame August 20, 1968) for a left ankle sprain after a fall, and a subsequent annual wellness visit on October 15, 2026 (true frame October 15, 1968). Both are synthetic, and the fall does not echo a documented injury. A trip on an unseen edge in low-contrast light was chosen because reduced contrast sensitivity from macular degeneration is a recognized cause of falls, and it lets the wellness visit teach fall, home-safety, and driving review for an older adult with low vision who lives alone. The wellness visit uses the acuity recorded at the July retina visit rather than inventing a new measurement, and does not describe retina visits after July. Immunizations follow her synthetic record: the second zoster dose is given late without restarting the series, and pneumococcal, RSV, and tetanus vaccines are listed as due because none is on record. Its advance care planning names no real person as her health care agent.
- **Medications.** Intravitreal aflibercept is recorded as procedures, because the schema has no intravitreal route. The AREDS2 supplement is recorded as an intervention, because RxNorm has no single clinical drug for the full AREDS2 formula. The medication list is therefore empty.
- **Not used.** Biographies’ accounts of her relationships, the 1978 lawsuit, and secondhand reports that her vision loss was kept quiet were not needed for the clinical teaching and are not recorded. Causes of her parents’ deaths were not given in the cited source.
- **Focused visits.** The four retina follow-ups (the March consultation with the first injection, the second and third loading injections, and the first treat-and-extend visit in July) are documented as focused visits on the AAO macular degeneration Preferred Practice Pattern, with the CMID cataract and glaucoma eye-examination items and general depression and cognitive items. Each lists every item the protocol calls for at that point, with its interval and status. Synthetic findings introduced: the fundus descriptions, a small subconjunctival hemorrhage after the first injection that resolved, the post-injection optic nerve perfusion checks, and the timing of the low-vision rehabilitation steps (referral at the consultation, evaluation in May, completion with a daytime local driving clearance by July), which agree with the goal outcomes and the later wellness visit. Protocol deviations recorded instead of invented results: no fluorescein or OCT angiography at diagnosis (treatment began on OCT alone; the response to loading supports the diagnosis), and the post-injection pressure check was made by optic nerve perfusion rather than a second pressure reading.
- **Consultation.** The retina referral and consultation are synthetic and written for this case. Dr. Tanabe's examination repeats the focused note of the consultation day, and her recommendations agree with what followed: three monthly aflibercept loading doses and then treat-and-extend; the AREDS2 supplement and daily Amsler checks started that day; fluorescein or OCT angiography held in reserve for a poor or atypical response, and not needed because the response to loading was typical; and the low-vision referral with a home fall-risk review and driving assessment, which later cleared her for short local daytime driving. Judgment calls: until that assessment the consultant limits her to short local daytime routes, on the strength of the right-eye acuity; and the after-injection check is recorded as optic nerve perfusion and counting fingers, matching the recorded deviation, not as a second pressure reading.
- **Presenting concern.** The intake documents list the presenting concern (PRB-004) rather than the macular degeneration in both eyes, which is recorded from the retina consultation, where OCT made the diagnosis. The presenting-concern problem is synthetic (**S**); it is resolved, superseded by the diagnosis, from that visit on.
- O’Keeffe died in 1986, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
